248 reports of this reaction
1.6% of all ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE reports
#15 most reported adverse reaction
GASTROOESOPHAGEAL REFLUX DISEASE is the #15 most commonly reported adverse reaction for ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, manufactured by Haleon US Holdings LLC. There are 248 FDA adverse event reports linking ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE to GASTROOESOPHAGEAL REFLUX DISEASE. This represents approximately 1.6% of all 15,305 adverse event reports for this drug.
Patients taking ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE who experience gastrooesophageal reflux disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROOESOPHAGEAL REFLUX DISEASE is a less commonly reported adverse event for ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, but still significant enough to appear in the safety profile.
In addition to gastrooesophageal reflux disease, the following adverse reactions have been reported for ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE:
The following drugs have also been linked to gastrooesophageal reflux disease in FDA adverse event reports:
GASTROOESOPHAGEAL REFLUX DISEASE has been reported as an adverse event in 248 FDA reports for ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROOESOPHAGEAL REFLUX DISEASE accounts for approximately 1.6% of all adverse event reports for ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, making it a notable side effect.
If you experience gastrooesophageal reflux disease while taking ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.